EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.

Alkermes ALKS underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings ...

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our ...

UBS upgraded Alkermes (NASDAQ: ALKS) from Neutral to Buy on Tuesday, raising its price target to $42.00 from $33.00. The upgrade reflects UBS’s growing confidence in the company’s orexin ...

Alkermes (NASDAQ:ALKS) stock gains as UBS upgrades the stock citing promising prospects for its OX2R agonist ALKS-2680 in treating sleep disorders. Read more here.

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $42.00. The company’s shares ...

Revenue Growth: Alkermes's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -12.52%.

UBS has upgraded Alkermes from Neutral to Buy, raising its price target to $42.00, driven by confidence in the company’s orexin receptor drug candidate, ALKS-2680.

View the latest Alkermes PLC (ALKS) stock price, news, historical charts, analyst ratings and financial information from WSJ.